UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

 

For the Month of: November 2017

 

Commission File Number: 001-37847

 

MOTIF BIO PLC

(Exact name of registrant as specified in its charter)

 

125 Park Avenue

25th Floor

New York, New York 10011

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

 

 


 

MOTIF BIO PLC

FORM 6-K

 

MOTIF BIO SECURES UP TO US$20 MILLION DEBT FINANCING

 

On November 15, 2017, Motif Bio plc (the “Company”) issued a press release, a copy of which is attached as Exhibit 99.1 to this report on Form 6-K, announcing that the Company has entered into an agreement for up to US$20 million in debt financing with Hercules Capital, Inc. The terms of the agreement are further described in the press release, which is attached as Exhibit 99.1 to this report on Form 6-K.

 

The information contained in Exhibit 99.1 is being furnished to the U.S. Securities and Exchange Commission (the “Commission”) and shall not be deemed incorporated by reference into any of the registrant’s registration statements or other filing with the Commission.

 

Exhibits

 

 

 

 

 

Exhibit 99.1

 

Press release issued by Motif Bio plc, dated November 15, 2017, entitled “Motif Bio secures up to US$20 million debt financing.”

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

MOTIF BIO PLC

 

 

 

 

 

By:

/s/ Robert Dickey IV

 

Name: Robert Dickey IV

 

Title: Chief Financial Officer

 

 

Date: November 15, 2017

 

 

3